Drugs / KK3910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06823947 | Apr 2025 → Dec 2027 expected | essential hypertension | Kyowa Kirin, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK3910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06823947 ↗ |
| Route | Subcutaneous | “KK3910 is administered single dose or multiple dose by SC injection.” NCT06823947 ↗ |